RhumbLine Advisers’s Vaxcyte PCVX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $6.45M | Buy |
198,487
+17,257
| +10% | +$561K | 0.01% | 1282 |
|
|
2025
Q1 | $6.84M | Buy |
181,230
+9,416
| +5% | +$356K | 0.01% | 1202 |
|
|
2024
Q4 | $14.1M | Buy |
171,814
+7,711
| +5% | +$631K | 0.01% | 893 |
|
|
2024
Q3 | $18.8M | Buy |
164,103
+4,808
| +3% | +$549K | 0.02% | 750 |
|
|
2024
Q2 | $12M | Buy |
159,295
+11,001
| +7% | +$831K | 0.01% | 945 |
|
|
2024
Q1 | $10.1M | Buy |
148,294
+17,743
| +14% | +$1.21M | 0.01% | 1036 |
|
|
2023
Q4 | $8.2M | Buy |
130,551
+241
| +0.2% | +$15.1K | 0.01% | 1156 |
|
|
2023
Q3 | $6.64M | Buy |
130,310
+6,131
| +5% | +$313K | 0.01% | 1197 |
|
|
2023
Q2 | $6.2M | Buy |
124,179
+29,005
| +30% | +$1.45M | 0.01% | 1254 |
|
|
2023
Q1 | $3.57M | Buy |
95,174
+3,377
| +4% | +$127K | ﹤0.01% | 1510 |
|
|
2022
Q4 | $4.4M | Buy |
91,797
+23,567
| +35% | +$1.13M | 0.01% | 1354 |
|
|
2022
Q3 | $1.64M | Buy |
68,230
+6,682
| +11% | +$160K | ﹤0.01% | 1867 |
|
|
2022
Q2 | $1.34M | Buy |
61,548
+10,759
| +21% | +$234K | ﹤0.01% | 1989 |
|
|
2022
Q1 | $1.23M | Buy |
50,789
+3,852
| +8% | +$93.1K | ﹤0.01% | 2049 |
|
|
2021
Q4 | $1.12M | Sell |
46,937
-536
| -1% | -$12.8K | ﹤0.01% | 2162 |
|
|
2021
Q3 | $1.2M | Buy |
47,473
+2,127
| +5% | +$53.9K | ﹤0.01% | 2149 |
|
|
2021
Q2 | $1.02M | Buy |
45,346
+16,763
| +59% | +$377K | ﹤0.01% | 2238 |
|
|
2021
Q1 | $565K | Buy |
28,583
+6,186
| +28% | +$122K | ﹤0.01% | 2435 |
|
|
2020
Q4 | $595K | Buy |
22,397
+1,996
| +10% | +$53K | ﹤0.01% | 2368 |
|
|
2020
Q3 | $1.01M | Buy |
+20,401
| New | +$1.01M | ﹤0.01% | 1991 |
|